Literature DB >> 15071488

Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.

A Mugellini1, P Preti, A Zoppi, L Corradi, E Fogari, G Derosa, R Fogari.   

Abstract

The aim of this double-blind, double-dummy, parallel group study was to compare the effects of delapril-manidipine combination vs a irbesartan-hydrochlorothiazide combination on plasma tissue plasminogen activator (t-PA) and plasmogen activator inhibitor type I (PAI-l) activities in hypertensive patients with type II diabetes mellitus. After a 4-week run-in placebo period, 80 patients (37 male and 43 female), aged 41-65 years, were randomly allocated to an 8-week treatment with delapril 30 mg once daily or irbesartan 150 mg once daily. Thereafter, manidipine l0 mg once daily was added to delapril treatment and hydrochlorothiazide 12.5 mg to irbesartan treatment for a further 8 weeks. Blood pressure (BP), plasma t-PA and PAI-l activities were evaluated at the end of the run-in period, after 4-week monotherapy treatments, and at the end of the combination treatment periods. Both combination treatments, delapril-manidipine and irbesartan-hydrochlorothiazide, produced a greater reduction in systolic BP/diastolic BP (SBP/DBP) values (-27.6/21.8 mmHg and -26.4/20.2 mmHg, respectively) than the respective monotherapies (-15.2/11.7 mmHg with delapril and -16.3/11.3 mmHg with irbesartan). Delapril monotherapy significantly decreased plasma PAI-l activity (-10.4 IU/mI; P<0.05). The addition of manidipine produced a significant increase in t-PA activity (+0.27 IU/mI); P<0.05). Irbesartan monotherapy did not significantly affect the fibrinolytic balance, whereas the addition of hydrochlorothiazide worsened it, producing a significant increase in PAI-l activity (+9.5 IU/ml; P<0.05). In hypertensive patients with type II diabetes mellitus, the combination delapril-manidipine may determine a greater improvement of the fibrinolytic function than the respective monotherapy, while the association irbesartan-hydrochlorothiazide may worsen it.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15071488     DOI: 10.1038/sj.jhh.1001726

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  9 in total

Review 1.  Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia.

Authors:  Sirirat Reungjui; Thongchai Pratipanawatr; Richard J Johnson; Takahiko Nakagawa
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-09       Impact factor: 2.894

Review 2.  Combination delapril/manidipine as antihypertensive therapy in high-risk patients.

Authors:  Roberto Fogari; Amedeo Mugellini; Maria Circelli; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.

Authors:  Punnaka Pongpanich; Pasvich Pitakpaiboonkul; Kullaya Takkavatakarn; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

4.  Delapril/manidipine.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  Thiazide Diuretic-Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials.

Authors:  Jill J Hall; Dean T Eurich; Danielle Nagy; Lisa Tjosvold; John-Michael Gamble
Journal:  J Gen Intern Med       Date:  2020-03-10       Impact factor: 5.128

6.  Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination.

Authors:  Giuseppe Derosa; Sibilla At Salvadeo
Journal:  Integr Blood Press Control       Date:  2010-05-19

7.  Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial.

Authors:  Masahiro Takihata; Akinobu Nakamura; Yoshinobu Kondo; Satsuki Kawasaki; Mari Kimura; Yasuo Terauchi
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

Review 8.  Manidipine-delapril combination in the management of hypertension.

Authors:  Manuel Luque Otero
Journal:  Vasc Health Risk Manag       Date:  2007

Review 9.  Manidipine: an antihypertensive drug with positive effects on metabolic parameters and adrenergic tone in patients with diabetes.

Authors:  Margarita SaizSatjes; Francisco Javier Martinez-Martin
Journal:  Drugs Context       Date:  2018-01-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.